AKT1 and hepatocellular carcinoma: Although multiple previous clinical trials did not provide promising evidence for clinical application in HCC and only some inhibitors of PI3K are currently approved for the clinical treatment of human cancers42,47, the PI3K/AKT pathway still renders attractive therapeutic options for HCC treatments.